Amylyx Pharmaceuticals (NASDAQ: AMLX) net income
Amylyx Pharmaceuticals reported a net loss of $144.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $301.7m. Earnings per share were −$1.53.
Amylyx Pharmaceuticals's best year of the last 5 was fiscal 2023. It reported a loss in 4 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$144.7m | — | — | −$1.53 |
| 2024 | −$301.7m | −712.4% | −345.4% | −$4.43 |
| 2023 | $49.3m | — | 12.9% | $0.73 |
| 2022 | −$198.4m | — | −892.4% | −$3.39 |
| 2021 | −$87.9m | — | −30,853.0% | −$13.35 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Amylyx Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Amylyx Pharmaceuticals ranks 379th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 377th | Entrada Therapeutics | −$143.8m | −565.5% |
| 378th | Charles River Laboratories | −$144.3m | −3.6% |
| 379th | Amylyx Pharmaceuticals | −$144.7m | — |
| 380th | AbCellera Biologics | −$146.4m | −194.9% |
| 381st | Caribou Biosciences | −$148.1m | −1,327.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Amylyx Pharmaceuticals
- How much did Amylyx Pharmaceuticals earn in fiscal 2025?
- Amylyx Pharmaceuticals reported a net loss of $144.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $301.7m.
- What are the earnings per share of Amylyx Pharmaceuticals?
- They were −$1.53 in fiscal 2025, compared with −$4.43 in fiscal 2024.
- What was the most profitable year for Amylyx Pharmaceuticals?
- Of its last 5 fiscal years, fiscal 2023, with $49.3m.
- Where does Amylyx Pharmaceuticals rank in its sector by net income?
- It ranks 379th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Amylyx Pharmaceuticals come from?
- From the annual report (Form 10-K) that Amylyx Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Amylyx Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Amylyx Pharmaceuticals: the Amylyx Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.